YCC-1 Xenograft Model Service for Gastric Cancer

The YCC-1 xenograft model offers a robust preclinical platform for evaluating therapeutic candidates against gastric adenocarcinoma, faithfully recapitulating the histopathological and molecular features of human disease. Alfa Cytology provides validated YCC-1 xenograft model services designed to accelerate your oncology drug discovery pipeline with reliable, reproducible, and publication-ready data.

Overview of YCC-1 Xenograft Model for Gastric Cancer

The YCC-1 cell line was established from the malignant ascites of a gastric cancer patient at the Yonsei Cancer Center (Seoul, South Korea), representing a well-characterized model of human gastric adenocarcinoma. This cell line carries a mutant p53 status and exhibits strong tumorigenic potential in immunocompromised hosts, making it a valuable resource for studying gastric cancer progression, metastasis, and therapeutic response. YCC-1 demonstrates robust HER2/neu protein expression (scored as +++) and has been extensively utilized in preclinical studies evaluating targeted biologic therapies, including trastuzumab-based combination regimens, as well as conventional chemotherapeutic agents such as doxorubicin, cisplatin, and paclitaxel.

When implanted subcutaneously or orthotopically into immunodeficient mice, YCC-1 forms progressively growing tumors that retain key molecular signatures of the parental cell line, including mutant p53 expression and elevated HER2 levels. The xenograft model supports both monotherapy and combination therapy evaluation, with measurable endpoints including tumor volume, body weight monitoring, histopathological analysis, and biomarker profiling. Its established use in academic and industrial research underscores its reliability as a translational tool for bridging in vitro findings to in vivo efficacy assessments in gastric cancer drug development.

Figure 1. Effects of iBET-151 on cell cycle arrest, apoptosis and anchorage-independent growth. (Kang, Sun Kyoung, et al., 2021)

Cell Line Information: YCC-1

The YCC-1 cell line is a human gastric adenocarcinoma cell line with the following documented characteristics:

Our Services

Alfa Cytology leverages its extensive expertise in oncology preclinical research to deliver validated YCC-1 xenograft model services tailored to your drug development needs. Our platform integrates rigorous quality control, standardized protocols, and comprehensive endpoint analysis --- including tumor growth monitoring, histopathology, immunohistochemistry, and biomarker profiling --- to ensure data integrity and translational relevance. Whether you are evaluating novel targeted agents, combination regimens, or biologics, our team provides end-to-end support from study design to final report, enabling confident decision-making in your gastric cancer therapeutic pipeline.

Workflow of YCC-1 Xenograft Model Construction

The construction of the YCC-1 xenograft model follows a systematic, quality-controlled workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. Each stage is optimized to maintain the molecular fidelity of the YCC-1 cell line while enabling robust therapeutic evaluation.

1. Cell Preparation and Quality Control. YCC-1 cells are expanded under standardized culture conditions (RPMI 1640 or DMEM, 10% FBS, 37 degrees C, 5% CO2) and subjected to pre-implantation quality checks, including mycoplasma testing, viability assessment (trypan blue exclusion >95%), and authentication verification. Cells are harvested at logarithmic growth phase to maximize engraftment efficiency.
2. Mouse Model Selection and Preparation. Immunodeficient mice (typically BALB/c nude or NOD-SCID) are acclimatized for one week under pathogen-free conditions. Animals are randomized by body weight and assigned to treatment groups, with all procedures conducted under institutional animal care and use committee (IACUC) approval.
3. Tumor Cell Inoculation. YCC-1 cells are resuspended in a 1:1 mixture of serum-free medium and Matrigel (or PBS for subcutaneous models) at a concentration of 1x10^6 to 5x10^6 cells per 100-200 uL. For subcutaneous xenografts, cells are injected into the flank region; for orthotopic models, cells are delivered via surgical implantation into the gastric wall.
4. Tumor Monitoring and Randomization. Tumor growth is monitored twice weekly using caliper measurements in two perpendicular dimensions. Tumor volume is calculated using the formula V = (L x W^2) / 2. Once tumors reach a palpable size (typically 50-100 mm3), mice are randomized into treatment and vehicle control groups to minimize inter-group variability.
5. Therapeutic Intervention and Endpoint Assessment. Test compounds are administered according to the predefined dosing schedule (route, frequency, and duration). Throughout the study, body weight, tumor dimensions, and clinical signs are recorded. At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E), immunohistochemistry (IHC), and molecular profiling.
6. Data Analysis and Reporting. All data are analyzed using appropriate statistical methods (e.g., two-way ANOVA for tumor growth curves, Student's t-test for endpoint comparisons). Results are compiled into a comprehensive study report including tumor growth inhibition (TGI) calculations, Kaplan-Meier survival curves (if applicable), and representative histological images.

Figure 2. YCC-1 xenograft model construction workflow.

Case Study-YCC-1 Xenograft Model Development

In a representative preclinical study, YCC-1 cells were implanted subcutaneously into immunodeficient mice to establish a gastric cancer xenograft model for evaluating the efficacy of a novel therapeutic candidate. Following successful engraftment and tumor growth monitoring, animals were randomized and treated according to the experimental protocol. Endpoint analysis demonstrated measurable tumor growth inhibition, with histopathological examination confirming maintained adenocarcinoma morphology and biomarker expression consistent with the parental YCC-1 cell line. Comprehensive data packages including tumor volume curves, body weight records, and IHC staining results were generated to support downstream drug development decisions. (Specific quantitative data are available upon request and can be customized to align with client study objectives.)

Why Choose Alfa Cytology?

Alfa Cytology stands out as a trusted partner for gastric cancer preclinical research, offering validated YCC-1 xenograft models backed by rigorous scientific expertise and operational excellence. Our commitment to quality, transparency, and client collaboration ensures that every study delivers actionable insights for your drug development program.

• Validated cell line authentication and mycoplasma-free guarantees for every study.
• Customizable study designs accommodating monotherapy, combination therapy, and dose-escalation protocols.
• Comprehensive endpoint analysis including tumor growth kinetics, histopathology, immunohistochemistry, and biomarker quantification.
• Experienced in vivo oncology team with proven track record in xenograft model development across multiple cancer indications.
• Strict adherence to IACUC guidelines and AAALAC-accredited animal care standards ensuring ethical and regulatory compliance.
• Rapid project turnaround with dedicated project management and transparent milestone reporting.
• Competitive pricing with no hidden costs, supported by detailed quotations and flexible contract terms.

Contact Us

Ready to accelerate your gastric cancer drug discovery program with a validated YCC-1 xenograft model? Contact us today to discuss your project requirements, request a customized study proposal, or schedule a consultation with our scientific team. Reach out to us via email or through our online inquiry form, and let Alfa Cytology be your partner in transforming preclinical data into clinical success. Please reach out to us today via our inquiry form or email to learn more about our YCC-1 Xenograft Model services.

For research use only. Not intended for any clinical use.